Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 10/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880900 | 0.92 | SSTR5 (0.49) | SSTR5HRH1HTR2BKMT2ABCHE | |
| SCHEMBL1870157 | 0.90 | TLR9 (0.42) | SSTR5HRH1HTR2BALDH1A1KDM4E | |
| SCHEMBL1874337 | 0.90 | SSTR5 (0.49) | SSTR5KDM4EKMT2ANPSR1BCHE | |
| SCHEMBL1882261 | 0.89 | BCHE (0.41) | SSTR5HRH1HTR2BKMT2ABCHE | |
| SCHEMBL1876358 | 0.89 | SSTR5 (0.41) | SSTR5HRH1HTR2BALDH1A1KDM4E | |
| SCHEMBL1874533 | 0.89 | CCR5 (0.42) | SSTR5ALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL1875582 | 0.88 | SSTR5 (0.47) | SSTR5HRH1ALDH1A1KDM4EKCNH2 | |
| SCHEMBL1873520 | 0.88 | SSTR5 (0.51) | SSTR5HRH1HTR2BALDH1A1KDM4E | |
| SCHEMBL1878189 | 0.88 | SSTR5 (0.48) | SSTR5KMT2ABCHEACHE | |
| SCHEMBL1877332 | 0.85 | SSTR5 (0.48) | SSTR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939661-B2 | Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | claimed |
| EP-2066658-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-10 | — | — | EP | claimed |
| WO-2008031735-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | claimed |
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-03-13 | — | — | US | claimed |
| US-7939661-B2 | Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2066658-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031735-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | SSTR5, SSTR3, NPY5R | SSTR5 1/4885HRH1 97/4885HTR2B 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.